MODULIGHT OYJ

8/25/2025 10:15 am EEST

This is a translated version of "Kasvua kvanttilaskentaprojektin tukemana" report, published on 8/25/2025

Antti Siltanen
+358 45 119 6869
antti.siltanen@inderes.fi

INDERES CORPORATE CUSTOMER

COMPANY REPORT

Growth supported by quantum computing project

Modulight's revenue grew by triple-digit percentages, its operating loss was cut in half, and our estimates were exceeded. The company reported brisk trading during the summer, and revenue was also supported by the partial recognition of the quantum computing order. On the whole, the company is progressing in line with our expectations, so the estimate changes will be minor this time. However, the positive development of the gross margin will raise our earnings forecasts somewhat. We reiterate our Accumulate recommendation and raise the target price to EUR 1.6 (was EUR 1.5) based on the changes to our estimates.

The positive revenue trend of recent quarters continued

Modulight's Q2 revenue amounted to 1.96 MEUR and exceeded our forecast of 1.73 MEUR. Revenue grew by 103% from Q2'24 and by 22% from the previous quarter. Q2 was Modulight's best quarter in terms of revenue since the company started quarterly reporting (Q1'23). According to Modulight, orders received during the summer were significantly higher than normal, a trend that continued into Q3. The number of medical lasers to be installed increased during the quarter, despite some delays in installation. An increase in installed devices supports future treatment-session-based revenue generated by the PPT model and is, we understand, closely linked to ongoing Phase III clinical trials. The tariff situation and the weakened dollar in the US could impact the company negatively, but the large share of services in the product mix will mitigate this impact.

Gross margin and earnings developed in the right direction

EBIT of -1.06 MEUR also beat our estimate of -1.72 MEUR. This outperformance is due to higher-than-expected revenue and a better gross margin. Operating costs were largely in line with our expectations. Cash flow from operating and investing activities was -1.75 MEUR. According to our estimates, the increase in trade receivables weakened cash flow, which we believe was related to the large number of orders at the end of the reporting period. We expect trade receivables to translate into improved cash flow in Q3. Net cash at the end of the period amounted to 8.78 MEUR (Q1'24: 15.02 MEUR). At the current burn rate, net cash will suffice for roughly another year and a half. It is clear that the business needs to grow fairly rapidly upward for current cash reserves to be sufficient.

Earnings estimates raised based on gross margin development

Our revenue estimates remain unchanged for now. Q2 exceeded our expectations, but according to management comments, a significant portion of the quantum computing project has already been recognized as income, which will be reflected in H2 accordingly. The gross margin trend appears to be slightly better than we expected, which moderately raises our earnings forecasts for the coming years.

Positive growth signals versus cash burn create a contradiction in our standing

The valuation of the share is uncertain due to the unpredictability of earnings and cash flow turnaround. The valuation relies heavily on future projections, which carry a high degree of forecasting risk. Success in growth during the last few quarters increases confidence in the progress of the investment story. On the other hand, the continued decline in cash reserves increases the risk profile.

EV/S multiples are 7x-5x for 2025-2026, which we find cautiously attractive due to the substantial growth potential. The DCF model suggests a moderate upside for the stock. We reiterate our Accumulate recommendation following the good development that has continued at the beginning of the year. We emphasize that a sufficient expected return on the stock requires a continuation of good performance, which is difficult to assess at this stage. The investment involves high risk, which can be realized if the budding growth slows down or is interrupted.

Recommendation
Accumulate
(was Accumulate)

Target price:
EUR 1.60
(was EUR 1.50)

Share price:
EUR 1.39

Business risk
●●●●●

Valuation risk
●●●●○

	2024	2025e	2026e	2027e
Revenue	4.1	8.0	10.8	15.3
growth-%	2%	95%	36%	41%
EBIT adj.	-8.3	-5.4	-4.5	-2.0
Net Income	-6.5	-5.2	-3.7	-1.8
EPS (adj.)	-0.15	-0.12	-0.09	-0.04
P/E (adj.)	neg.	neg.	neg.	neg.
P/B	1.0	1.3	1.5	1.5
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %
EV/EBIT (adj.)	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	43.4
EV/S	8.3	6.7	5.3	3.9

Source: Inderes

Guidance

Modulight does not provide any guidance.

Share price



Source: Millistream Market Data AB

Revenue and EBIT-% (adj.)



Source: Inderes

EPS and dividend



Source: Inderes

Value drivers

- A defensive market with growth well into the future
- Technological expertise, ability to tailor products and build cloud services gives Modulight a competitive advantage
- A model based on license fees and pay-per-treatment pricing can be highly scalable if successful

Risk factors

- Medical development projects progress slowly, and their commercialization is uncertain.
- Growth is poorly predictable
- Low visibility of projects and their progress
- Immature and concentrated customer base brings more risk

Valuation	2025e	2026e	2027e
Share price	1.39	1.39	1.39
Number of shares, millions	42.6	42.6	42.6
Market cap	59	59	59
EV	53	57	59
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/B	1.3	1.5	1.5
P/S	7.4	5.5	3.9
EV/Sales	6.7	5.3	3.9
EV/EBITDA	neg.	neg.	43.4
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Estimates exceeded with the support of the quantum computing project

Estimates vs. outcome

- Modulight's Q2'25 revenue was 1.96 MEUR, which exceeded our forecast (1.73 MEUR) by 13%.
- Year-on-year growth amounted to 103% and quarter-on-quarter growth to 22%.
- This growth is partly explained by the recognition of a significant portion of the 0.8 MEUR quantum computing order as income during Q2.
- According to the company, regulatory processes have caused delays in the beginning of the year. Longer-than-expected processes are quite typical in the sector.
- EBIT was -1.06 MEUR. The loss was lower than we expected (-2.08).
- In addition to higher-than-expected revenue and gross margin, the cost structure and depreciation were in line with our expectations.
- Cash flow from operating and investing activities was -1.75 MEUR.
- Modulight's working capital fluctuates quarterly, and it now tied up 0.38 MEUR, which weakened cash flow. This is due to an increase in trade receivables, which we expect will return to normal in the next quarter and improve cash flow.
- Net cash at the end of the period amounted to 8.78 MEUR (Q2'24: 15.02 MEUR).
- At the current burn rate, net cash will last about another year and a half. Therefore, maintaining sufficient cash reserves requires a continued positive business trend at a fairly rapid pace and significantly higher revenue than current levels.

Estimates	Q2'24	Q2'25	Q2'25e	Q2'25e	Consensus		Difference (%)	2025e
MEUR / EUR	Comparison	Actualized	Inderes	Consensus	Low	High	Act. vs. inderes	Inderes
Revenue	0.97	1.96	1.73				13%	8.0
EBIT	-2.05	-1.06	-1.72				39%	-5.4
EPS (reported)	-0.05		-0.04					-0.12
Revenue growth-%	-12.8 %	103.3 %	79.7 %				23,6 pp	95.3 %
EBIT-% (adj.)	-212.1 %	-53.8 %	-99.0 %				45,2 pp	-67.2 %

Source: Inderes

Moderate increases in earnings estimates based on gross margin development

Estimate revisions

- Our revenue estimates remain unchanged for now.
- Q2 exceeded our preliminary expectations, but according to management comments, a significant portion of the quantum computing project has already been recognized as income, which will be reflected in H2 accordingly.
- We are therefore adjusting our forecasts for the remainder of the year slightly downward accordingly.
- The gross margin trend appears to be slightly better than we expected, which moderately raises our earnings forecasts for the coming years.
- While our earnings forecasts will increase significantly in percentage terms, the changes in euros will remain fairly small.

Estimate revisions	2025e	2025e	Change	2026e	2026e	Change	2027e	2027e	Change
MEUR / EUR	Old	New	%	Old	New	%	Old	New	%
Revenue	8.0	8.0	0%	10.8	10.8	0%	15.3	15.3	0%
EBITDA	-1.7	-1.3	23%	-0.5	-0.4	21%	1.0	1.4	31%
EBIT	-5.8	-5.4	7%	-4.6	-4.5	2%	-2.4	-2.0	14%
EPS (excl. NRIs)	-0.13	-0.12	3%	-0.09	-0.09	3%	-0.06	-0.04	29%
DPS	0.00	0.00		0.00	0.00		0.00	0.00	

Source: Inderes

Valuation picture remains attractive

EV/S ratios are tolerable, but require continued growth

Because of the loss-making business, we cannot use earnings-based multiples in valuation but instead rely on revenue-based EV/S ratios and DCF calculation that models the present value of future cash flows. The valuation is inherently imprecise as it is based on forecasts with little visibility, although we believe the situation has improved. It is difficult to assess the earnings turnaround, which poses challenges for fair value measurement.

On our updated estimates, EV/S multiples for 2025-2026 are 6.7x and 5.3x. Typically, the stock has been valued at around 8x current-year multiples. Compared to recent years, the multiples have become more attractive, especially when taking into account the increased order book and the outlook for the current year. The multiples are still high compared to Lumibird SA, which we consider the most suitable peer (EV/S: 2.4x and 2.4x) and the peer group of laser manufacturers (4.8x-5.4x). The median for large and highly profitable medical device companies is 5.7x and 6.2x. The industry's multiples have decreased clearly during Q1.

Given the growing order book and increased visibility, we believe the EV/S multiples are acceptable. The stock's valuation assumes continued good performance, which would justify the relatively high absolute multiples. A low starting point supports the possibility of strong relative revenue growth. We emphasize that the positive signs of business improvement are still early and caution is, therefore, still warranted. However, if developments remain positive, we also see the conditions for multiple expansion.

DCF model points to moderate upside

The baseline case in our DCF calculation gives the stock a value of EUR 1.6. We use a cost of capital of 11.5% corresponding to the risk profile. The model thus suggests a moderate upside for the stock, above the required return. In the positive scenario, the DCF is EUR 2.8 and in the negative scenario EUR 0.3. The main factor explaining the differences between the scenarios is revenue growth, which is followed by profitability. In particular, the higher terminal profitability (EBIT of 30%) in the positive scenario has a clear upward effect on the value. In the negative scenario, terminal profitability remains at 20%. We note that the scenarios do not represent our view of the best and worst possible path for the business but are intended to provide investors with a perspective on the sensitivity of the valuation assumptions used, which in the case of Modulight is high. More information on the scenarios can be found in the Initiation of coverage report.

We reiterate our recommendation and raise our target price slightly

We reiterate our Accumulate recommendation for the share and raise our target price to EUR 1.6 (was EUR 1.5) based on estimate hikes. The EV/S multiple and the DCF model with its scenarios are central to this view. The DCF suggests a significant upside or downside for the share in high and low growth scenarios. In case the low estimate materializes, the risk of permanently losing capital is considerable.

Valuation	2025e	2026e	2027e
Share price	1.39	1.39	1.39
Number of shares, millions	42.6	42.6	42.6
Market cap	59	59	59
EV	53	57	59
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/B	1.3	1.5	1.5
P/S	7.4	5.5	3.9
EV/Sales	6.7	5.3	3.9
EV/EBITDA	neg.	neg.	43.4
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes



Valuation table

Valuation	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e
Share price		11.4	2.95	0.90	1.10	1.39	1.39	1.39	1.39
Number of shares, millions	30.7	42.6	42.6	42.6	42.6	42.6	42.6	42.6	42.6
Market cap		484	126	38	47	59	59	59	59
EV	3.9	430	90	20	34	53	57	59	58
P/E (adj.)	0.0	neg.	neg.	neg.	neg.	neg.	neg.	neg.	31.6
P/E	0.0	neg.	neg.	neg.	neg.	neg.	neg.	neg.	31.6
P/B	0.0	6.4	1.9	0.7	1.0	1.3	1.5	1.5	1.5
P/S	0.0	53.3	27.3	9.5	11.4	7.4	5.5	3.9	2.9
EV/Sales	0.4	47.4	19.6	4.9	8.3	6.7	5.3	3.9	2.8
EV/EBITDA	0.7	>100	neg.	neg.	neg.	neg.	neg.	43.4	9.8
EV/EBIT (adj.)	0.8	neg.	neg.	neg.	neg.	neg.	neg.	neg.	24.3
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	50.0 %
Dividend yield-%		0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	1.6 %

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years.

Peer group valuation

Peer group valuation	Market cap	EV	EV/EBIT		EV/EBITDA		EV/S		P/E		Dividend yield-%		P/B
Company	MEUR	MEUR	2025e	2026e	2025e	2026e	2025e	2026e	2025e	2026e	2025e	2026e	2025e
Carl Zeiss Meditech	3830	4426	12.1	18.8	9.9	13.8	2.1	2.1	14.4	23.2	2.5	2.0	1.8
Coherent Corp	11953	16795	20.2	28.3	16.2	19.9	3.9	4.2	30.4	54.5			2.0
IPG Photonics Corp	2960	2192	10.4		7.9	122.5	2.0	2.6	17.5				1.6
Lumentum	7119	8566	29.4	282.9	20.7	70.6	5.7	7.4	26.4	121.8			5.3
Lumibird SA	409	499	22.9	38.4	13.0	15.1	2.4	2.4	37.1	60.7			1.9
Medtronic	101368	118256	16.9	16.8	14.9	14.8	4.5	4.3	17.6	17.8	2.9	3.0	2.3
Nexstim	97	99		24.8		24.8	14.2	6.2		28.7			34.6
nLIGHT	1194	1114					6.3	6.6					
Optomed	74	70					4.5	4.8					3.3
Revenio Group	659	650	24.8	25.0	21.7	21.1	6.8	6.3	33.4	34.8	1.5	1.6	6.5
Stryker	128613	140660	33.9	29.4	30.9	26.6	8.1	7.3	37.9	32.7	0.7	0.8	8.0
Theralase	34	34					53.1	71.0					22.0
Xvivo Perfusion	515	496	122.4	48.8	56.7	31.1	9.0	6.7	158.4	38.9			3.0
Modulight Oyj (Inderes)	59	53	-9.9	-12.7	-40.7	-134.7	6.7	5.3	-11.5	-16.1	0.0	0.0	1.3
Average			32.5	57.0	21.3	36.0	9.4	10.1	41.5	45.9	1.9	1.9	7.7
Median			22.9	28.3	16.2	22.9	5.7	6.2	30.4	34.8	2.0	1.8	3.1
Diff-% to median			-143%	-145%	-352%	-688%	18%	-15%	-138%	-146%	-100%	-100%	-57%

Source: Refinitiv / Inderes

Income statement

Income statement	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25e	Q3'25e	Q4'25e	2025e	2026e	2027e	2028e
Revenue	4.0	1.1	1.0	0.6	1.4	4.1	1.6	2.0	1.9	2.5	8.0	10.8	15.3	20.7
Group	4.0	1.1	1.0	0.6	1.4	4.1	1.6	2.0	1.9	2.5	8.0	10.8	15.3	20.7
EBITDA	-8.5	-2.1	-1.2	-1.3	-1.0	-5.6	-0.6	0.0	-0.3	-0.4	-1.3	-0.4	1.4	5.9
Depreciation	-3.6	0.1	-0.8	-0.8	-1.2	-2.7	-1.0	-1.0	-1.0	-1.0	-4.1	-4.1	-3.4	-3.5
EBIT	-12.1	-2.0	-2.0	-2.1	-2.2	-8.3	-1.6	-1.1	-1.3	-1.4	-5.4	-4.5	-2.0	2.4
Net financial items	0.3	0.1	0.1	0.1	1.5	1.9	0.0	-0.1	0.2	0.2	0.2	0.8	-0.1	-0.1
PTP	-11.8	-1.9	-1.9	-2.0	-0.7	-6.5	-1.6	-1.1	-1.2	-1.3	-5.2	-3.7	-2.1	2.3
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	-0.4
Net earnings	-11.8	-1.9	-1.9	-2.0	-0.7	-6.5	-1.6	-1.1	-1.2	-1.3	-5.2	-3.7	-1.8	1.9
EPS (adj.)	-0.28	-0.04	-0.05	-0.05	-0.02	-0.15	-0.04	-0.03	-0.03	-0.03	-0.12	-0.09	-0.04	0.04
EPS (rep.)	-0.28	-0.04	-0.05	-0.05	-0.02	-0.15	-0.04	-0.03	-0.03	-0.03	-0.12	-0.09	-0.04	0.04

Key figures	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25e	Q3'25e	Q4'25e	2025e	2026e	2027e	2028e
Revenue growth-%	-12.5 %	-29.0 %	-12.8 %	57.6 %	40.3 %	1.7 %	51.5 %	103.3 %	196.9 %	77.0 %	95.3 %	35.6 %	41.4 %	35.1 %
Adjusted EBIT growth-%	55.7 %	3.9 %	-2.3 %	-31.4 %	-56.5 %	-31.3 %	-20.1 %	-48.5 %	-36.9 %	-35.7 %	-35.4 %	-16.5 %	-54.5 %	-217.2 %
EBITDA-%	-212.0 %	-196.0 %	-126.5 %	-199.7 %	-71.4 %	-136.7 %	-36.1 %	-2.2 %	-16.2 %	-15.1 %	-16.4 %	-3.9 %	8.9 %	28.7 %
Adjusted EBIT-%	-301.4 %	-186.6 %	-212.1 %	-329.4 %	-153.9 %	-203.5 %	-98.4 %	-53.8 %	-70.0 %	-55.9 %	-67.2 %	-41.4 %	-13.3 %	11.6 %
Net earnings-%	-293.1 %	-177.2 %	-202.0 %	-307.5 %	-46.0 %	-157.5 %	-100.3 %	-56.5 %	-62.1 %	-49.9 %	-64.6 %	-34.0 %	-11.5 %	9.1 %

Source: Inderes

Full-year earnings per share are calculated using the number of shares at year-end.

Balance sheet

Assets	2023	2024	2025e	2026e	2027e
Non-current assets	33.8	35.2	35.4	35.5	36.3
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	8.9	10.9	12.0	12.9	15.2
Tangible assets	24.9	24.3	23.4	22.5	21.0
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	30.2	21.1	16.9	13.4	11.4
Inventories	2.6	2.3	2.4	2.4	2.3
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	2.5	1.4	1.6	1.7	1.8
Cash and equivalents	25.1	17.4	12.9	9.3	7.2
Balance sheet total	64.0	56.3	52.3	48.9	47.6

Source: Inderes

Liabilities & equity	2023	2024	2025e	2026e	2027e
Equity	55.7	49.2	44.1	40.4	38.6
Share capital	0.1	0.1	0.1	0.1	0.1
Retained earnings	-19.7	-26.2	-31.3	-35.0	-36.8
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	75.3	75.3	75.3	75.3	75.3
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	4.5	2.8	5.0	5.0	5.0
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Interest bearing debt	4.5	2.8	5.0	5.0	5.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
Current liabilities	3.7	4.2	3.2	3.5	4.0
Interest bearing debt	2.0	1.8	2.0	2.0	2.0
Payables	1.7	2.5	1.2	1.5	2.0
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	63.9	56.3	52.3	48.9	47.6

DCF-calculation

DCF model	2024	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	TERM
Revenue growth-%	1.7 %	95.3 %	35.6 %	41.4 %	35.1 %	30.0 %	25.0 %	25.0 %	20.0 %	16.0 %	8.0 %	3.0 %	3.0 %
EBIT-%	-203.5 %	-67.2 %	-41.4 %	-13.3 %	11.6 %	12.0 %	16.0 %	20.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %
EBIT (operating profit)	-8.3	-5.4	-4.5	-2.0	2.4	3.2	5.4	8.4	11.1	12.9	13.9	14.3	
+ Depreciation	2.7	4.1	4.1	3.4	3.5	3.7	3.7	3.9	3.9	3.9	3.7	3.8	
- Paid taxes	0.0	0.0	0.0	0.4	-0.4	-0.6	-1.0	-1.5	-2.0	-2.3	-2.5	-2.5	
- Tax, financial expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	2.1	-1.6	0.2	0.5	-0.3	0.1	-0.8	-0.2	-0.4	-0.6	-0.4	-0.1	
Operating cash flow	-3.5	-2.9	-0.2	2.2	5.2	6.4	7.4	10.6	12.6	13.9	14.8	15.4	
+ Change in other long-term liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-4.1	-4.3	-4.2	-4.2	-4.1	-4.1	-4.0	-4.0	-4.0	-3.9	-3.9	-3.8	
Free operating cash flow	-7.6	-7.1	-4.4	-2.0	1.0	2.3	3.3	6.6	8.6	10.0	10.9	11.6	
+/- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	-7.6	-7.1	-4.4	-2.0	1.0	2.3	3.3	6.6	8.6	10.0	10.9	11.6	141
Discounted FCFF		-6.9	-3.8	-1.5	0.7	1.4	1.9	3.3	3.9	4.0	3.9	3.8	45.8
Sum of FCFF present value		56.6	63.4	67.2	68.8	68.0	66.6	64.8	61.4	57.5	53.5	49.6	45.8

Enterprise value DCF	56.6
- Interest bearing debt	-4.5
+ Cash and cash equivalents	17.4
-Minorities	0.0
-Dividend/capital return	0.0
Equity value DCF	69.4
Equity value DCF per share	1.6

WACC	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E)	10.0 %
Cost of debt	8.0 %
Equity Beta	1.90
Market risk premium	4.75%
Liquidity premium	0.50%
Risk free interest rate	2.5 %
Cost of equity	12.0 %
Weighted average cost of capital (WACC)	11.5 %

Source: Inderes



Summary

Income statement	2022	2023	2024	2025e	2026e
Revenue	4.6	4.0	4.1	8.0	10.8
EBITDA	-5.9	-8.5	-5.6	-1.3	-0.4
EBIT	-7.8	-12.1	-8.3	-5.4	-4.5
PTP	-8.6	-11.8	-6.5	-5.2	-3.7
Net Income	-8.6	-11.8	-6.5	-5.2	-3.7
Extraordinary items	0.0	0.0	0.0	0.0	0.0

Balance sheet	2022	2023	2024	2025e	2026e
Balance sheet total	78.3	64.0	56.3	52.3	48.9
Equity capital	67.6	55.7	49.2	44.1	40.4
Goodwill	0.0	0.0	0.0	0.0	0.0
Net debt	-35.6	-18.6	-12.9	-5.9	-2.3

Cash flow	2022	2023	2024	2025e	2026e
EBITDA	-5.9	-8.5	-5.6	-1.3	-0.4
Change in working capital	2.6	1.0	2.1	-1.6	0.2
Operating cash flow	-3.3	-7.5	-3.5	-2.9	-0.2
CAPEX	-13.7	-9.7	-4.1	-4.3	-4.2
Free cash flow	-17.0	-17.3	-7.6	-7.1	-4.4

Valuation multiples	2022	2023	2024	2025e	2026e
EV/S	19.6	4.9	8.3	6.7	5.3
EV/EBITDA	neg.	neg.	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	neg.
P/E (adj.)	neg.	neg.	neg.	neg.	neg.
P/B	1.9	0.7	1.0	1.3	1.5
Dividend-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %

Source: Inderes

Per share data	2022	2023	2024	2025e	2026e
EPS (reported)	-0.20	-0.28	-0.15	-0.12	-0.09
EPS (adj.)	-0.20	-0.28	-0.15	-0.12	-0.09
OCF / share	-0.08	-0.18	-0.08	-0.07	-0.01
OFCF / share	-0.40	-0.41	-0.18	-0.17	-0.10
Book value / share	1.59	1.31	1.16	1.03	0.95
Dividend / share	0.00	0.00	0.00	0.00	0.00

Growth and profitability	2022	2023	2024	2025e	2026e
Revenue growth-%	-49%	-12%	2%	95%	36%
EBITDA growth-%	-1428%	44%	-34%	-77%	-68%
EBIT (adj.) growth-%	935%	56%	-31%	-35%	-17%
EPS (adj.) growth-%	69%	38%	-45%	-20%	-29%
EBITDA-%	-129.0 %	-212.0 %	-136.7 %	-16.4 %	-3.9 %
EBIT (adj.)-%	-169.5 %	-301.4 %	-203.5 %	-67.2 %	-41.4 %
EBIT-%	-169.5 %	-301.4 %	-203.5 %	-67.2 %	-41.4 %
ROE-%	-11.9 %	-19.1 %	-12.3 %	-11.1 %	-8.7 %
ROI-%	-9.6 %	-17.6 %	-14.4 %	-10.3 %	-9.1 %
Equity ratio	86.3 %	87.1 %	87.5 %	84.3 %	82.6 %
Gearing	-52.7 %	-33.4 %	-26.1 %	-13.4 %	-5.7 %

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years. Per-share figures are calculated using the number of shares at year-end.

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
3/15/2023	Reduce	2.30 €	2.42 €
5/2/2023	Reduce	2.30 €	2.31 €
8/11/2023	Reduce	2.30 €	2.15 €
8/21/2023	Reduce	1.60 €	1.50 €
20.1023	Reduce	1.50 €	1.39 €
1/2/2023	Reduce	1.20 €	1.17 €
2/26/2024	Reduce	0.90 €	0.85 €
4/29/2024	Reduce	0.90 €	0.83 €
8/19/2024	Reduce	0.90 €	1.14 €
10/22/2024	Reduce	0.90 €	0.99 €
2/24/2025	Accumulate	1.30 €	1.15 €
4/28/2025	Accumulate	1.50 €	1.34 €
7/1/2025	Accumulate	1.50 €	1.22 €
8/25/2025	Accumulate	1.60 €	1.39 €



CONNECTING INVESTORS AND COMPANIES.

Inderes connects investors and listed companies.

We serve over 400 Nordic listed companies that want to better serve investors. The Inderes community is home to over 70,000 active investors.

We provide listed companies with solutions that enable seamless and effective investor relations. The Inderes service is built on four cornerstones for high-quality investor relations: Equity Research, Events, IR Software, and Annual General Meetings (AGM).

Inderes operates in Finland, Sweden, Norway, and Denmark and is listed on the Nasdaq First North Growth Market.

Inderes was created by investors, for investors.

Inderes Ab
Brunnsgatan
Stockholm
+358 10 219 4690

inderes.se

inderes.